207 related articles for article (PubMed ID: 22825770)
1. Circulating endothelial cell (CEC) as a diagnostic and prognostic marker in malignant pleural mesothelioma (MPM).
Yoneda K; Tanaka F; Kondo N; Orui H; Hashimoto M; Takuwa T; Matsumoto S; Okumura Y; Tsubota N; Sato A; Tsujimura T; Kuribayashi K; Fukuoka K; Nakano T; Hasegawa S
Ann Surg Oncol; 2012 Dec; 19(13):4229-37. PubMed ID: 22825770
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor cells (CTCs) in malignant pleural mesothelioma (MPM).
Yoneda K; Tanaka F; Kondo N; Hashimoto M; Takuwa T; Matsumoto S; Okumura Y; Tsubota N; Sato A; Tsujimura T; Kuribayashi K; Fukuoka K; Tabata C; Nakano T; Hasegawa S
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S472-80. PubMed ID: 24306661
[TBL] [Abstract][Full Text] [Related]
3. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
4. Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma.
Burt BM; Rodig SJ; Tilleman TR; Elbardissi AW; Bueno R; Sugarbaker DJ
Cancer; 2011 Nov; 117(22):5234-44. PubMed ID: 21523763
[TBL] [Abstract][Full Text] [Related]
5. Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report.
Beije N; Kraan J; den Bakker MA; Maat APWM; van der Leest C; Cornelissen R; Van NM; Martens JWM; Aerts JGJV; Sleijfer S
Cell Oncol (Dordr); 2017 Oct; 40(5):511-519. PubMed ID: 28577209
[TBL] [Abstract][Full Text] [Related]
6. Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.
Ohta Y; Shridhar V; Kalemkerian GP; Bright RK; Watanabe Y; Pass HI
Cancer; 1999 Jun; 85(12):2570-6. PubMed ID: 10375104
[TBL] [Abstract][Full Text] [Related]
7. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
[TBL] [Abstract][Full Text] [Related]
8. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
Borasio P; Berruti A; Billé A; Lausi P; Levra MG; Giardino R; Ardissone F
Eur J Cardiothorac Surg; 2008 Feb; 33(2):307-13. PubMed ID: 18164622
[TBL] [Abstract][Full Text] [Related]
9. Integrin-linked kinase, phosphorylated AKT and the prognosis of malignant pleural mesothelioma.
Watzka SB; Setinek U; Stubenberger EB; Tötsch M; Dekan G; Marcher M; Fleck T; Müller MR
Eur J Cardiothorac Surg; 2011 Feb; 39(2):180-4. PubMed ID: 20580243
[TBL] [Abstract][Full Text] [Related]
10. Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma.
Hirayama N; Tabata C; Tabata R; Maeda R; Yasumitsu A; Yamada S; Kuribayashi K; Fukuoka K; Nakano T
Respir Med; 2011 Jan; 105(1):137-42. PubMed ID: 21041073
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
Schneider J; Hoffmann H; Dienemann H; Herth FJ; Meister M; Muley T
J Thorac Oncol; 2008 Nov; 3(11):1317-24. PubMed ID: 18978568
[TBL] [Abstract][Full Text] [Related]
12. Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.
Kirschner MB; Pulford E; Hoda MA; Rozsas A; Griggs K; Cheng YY; Edelman JJ; Kao SC; Hyland R; Dong Y; László V; Klikovits T; Vallely MP; Grusch M; Hegedus B; Dome B; Klepetko W; van Zandwijk N; Klebe S; Reid G
Br J Cancer; 2015 Sep; 113(6):963-9. PubMed ID: 26263483
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
[TBL] [Abstract][Full Text] [Related]
14. Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma.
Raphael J; Massard C; Gong IY; Farace F; Margery J; Billiot F; Hollebecque A; Besse B; Soria JC; Planchard D
Cancer Biomark; 2015; 15(2):151-6. PubMed ID: 25519011
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis.
Ghanim B; Hoda MA; Winter MP; Klikovits T; Alimohammadi A; Hegedus B; Dome B; Grusch M; Arns M; Schenk P; Pohl W; Zielinski C; Filipits M; Klepetko W; Berger W
Ann Surg; 2012 Aug; 256(2):357-62. PubMed ID: 22750759
[TBL] [Abstract][Full Text] [Related]
16. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
Scherpereel A; Grigoriu B; Conti M; Gey T; Grégoire M; Copin MC; Devos P; Chahine B; Porte H; Lassalle P
Am J Respir Crit Care Med; 2006 May; 173(10):1155-60. PubMed ID: 16456138
[TBL] [Abstract][Full Text] [Related]
17. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
Iwahori K; Osaki T; Serada S; Fujimoto M; Suzuki H; Kishi Y; Yokoyama A; Hamada H; Fujii Y; Yamaguchi K; Hirashima T; Matsui K; Tachibana I; Nakamura Y; Kawase I; Naka T
Lung Cancer; 2008 Oct; 62(1):45-54. PubMed ID: 18394747
[TBL] [Abstract][Full Text] [Related]
18. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
Righi L; Papotti MG; Ceppi P; Billè A; Bacillo E; Molinaro L; Ruffini E; Scagliotti GV; Selvaggi G
J Clin Oncol; 2010 Mar; 28(9):1534-9. PubMed ID: 20177021
[TBL] [Abstract][Full Text] [Related]
19. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours.
Ohta Y; Shridhar V; Bright RK; Kalemkerian GP; Du W; Carbone M; Watanabe Y; Pass HI
Br J Cancer; 1999 Sep; 81(1):54-61. PubMed ID: 10487612
[TBL] [Abstract][Full Text] [Related]
20. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
